Literature DB >> 20443737

Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.

Peter D Burbelo1, Alexandra T Issa, Kathryn H Ching, Kathleen M Wyvill, Richard F Little, Michael J Iadarola, Joseph A Kovacs, Robert Yarchoan.   

Abstract

Antibody responses against lytic and latent Kaposi sarcoma (KS)-associated herpesvirus antigens were investigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma. Antibodies against the lytic antigen K8.1 were 5-fold higher in patients with MCD than those with KS, whereas antibodies to the sum of latent antigens v-cyclin and LANA were 27-fold higher in patients with KS, compared with patients with MCD (P < 001). The sum of anti-v-cyclin and anti-LANA antibody titers discriminated patients with KS from those with MCD and KS with 93% sensitivity and 83% specificity. These results suggest that antibody responses to lytic and latent KS-associated herpesvirus antigens differ in these diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20443737      PMCID： PMC2873114          DOI： 10.1086/652869

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

2.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Chuang-Jiun Chiou; Lynn J Poole; Peter S Kim; Dolores M Ciufo; Jennifer S Cannon; Colette M ap Rhys; Donald J Alcendor; Jian-Chao Zong; Richard F Ambinder; Gary S Hayward
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

5.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

6.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

7.  Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.

Authors:  Peter D Burbelo; Hannah P Leahy; Sandra Groot; Lisa R Bishop; Wendell Miley; Michael J Iadarola; Denise Whitby; Joseph A Kovacs
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

8.  Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities.

Authors:  E Cesarman; R G Nador; K Aozasa; G Delsol; J W Said; D M Knowles
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

9.  Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids.

Authors:  J R LaDuca; J L Love; L Z Abbott; S Dube; A E Freidman-Kien; B J Poiesz
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113
View more
  23 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.

Authors:  Roberto Flores; James J Goedert
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

Review 3.  Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems.

Authors:  Peter D Burbelo; Kathryn H Ching; Kathleen E Bren; Michael J Iadarola
Journal:  Expert Rev Proteomics       Date:  2011-06       Impact factor: 3.940

Review 4.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

5.  Quantitative determinations of anti-Kaposi sarcoma-associated herpesvirus antibody levels in men who have sex with men.

Authors:  Emile Gogineni; Vickie Marshall; Wendell Miley; Ahmad Bayat; Denise Whitby; Joseph A Kovacs; Peter D Burbelo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-28       Impact factor: 2.803

Review 6.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

7.  Emerging technologies for the detection of viral infections.

Authors:  Peter D Burbelo; Michael J Iadarola; Adrija Chaturvedi
Journal:  Future Virol       Date:  2018-12-14       Impact factor: 1.831

8.  Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Jeffrey I Cohen; Michael J Iadarola; Adriana Marques
Journal:  Clin Vaccine Immunol       Date:  2010-04-14

9.  No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome.

Authors:  Peter D Burbelo; Ahmad Bayat; Jason Wagner; Thomas B Nutman; James N Baraniuk; Michael J Iadarola
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

10.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.